Nuvalent, Inc.'s Chief Legal Officer, Deborah Ann Miller, recently conducted a sizable sale of company stock. On May 28, 2026, Ms. Miller sold 5,500 shares of the company's Class A Common Stock, realizing an aggregate value of approximately $593,100. This transaction followed the exercise of corresponding stock options to acquire an equal number of shares.
These transactions were managed under a Rule 10b5-1 trading plan, which Ms. Miller initially adopted on November 18, 2024. The sales comprised 5,500 shares and occurred at weighted average prices that ranged between $106.32 and $109.30 per share. Further detail from the filing footnotes indicates that actual transaction prices for these specific shares varied across multiple trades, spanning from a low of $105.87 to a high of $109.76.
Before executing the sales, Ms. Miller had acquired 5,500 shares of Class A Common Stock by exercising stock options at a price of $6.89 per share, totaling $37,895. The source material confirms that the shares underlying these options were fully vested when they were exercised.
Following the reported sale, Ms. Miller's direct holdings in Nuvalent Class A Common Stock amount to 59,634 shares. Investors seeking deeper insight into NUVL’s valuation metrics and executive trading history are directed toward comprehensive Pro Research Reports available on InvestingPro.
The news surrounding insider activity is contextualized by significant updates regarding Nuvalent's drug development pipeline. The company announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for neladalkib. This acceptance grants the investigational drug Priority Review status, with a target action date set for November 27, 2026.
Neladalkib is under review for treating advanced ALK-positive non-small cell lung cancer in patients who have been pre-treated with tyrosine kinase inhibitors. Beyond this application update, Nuvalent also presented updated clinical trial data for neladalkib at the 2026 ASCO meeting, which specifically highlighted median progression-free survival metrics in pretreated patient groups.
Furthermore, analysts maintained positive coverage following these developments. Stifel reiterated a Buy rating on Nuvalent shares subsequent to this data release. The company also presented data concerning its second investigational drug, zidesamtinib, at the 2026 AACR conference. These presentations included clinical data for patients who progressed on previous TKIs, alongside preclinical evidence demonstrating CNS penetrance and activity.
Complementing these developments, Nuvalent showcased ARROS-1 trial results in patients diagnosed with ROS1-positive non-small cell lung cancer who had received prior therapies. The accumulation of these advancements has positioned Nuvalent as a notable subject for investor attention.
The positive momentum was underscored by external analyst coverage. Bernstein initiated coverage on Nuvalent with an outperform rating and assigned a price target of $189.00, citing the potential value associated with both neladalkib and zidesamtinib. The general market data provided shows NUVL trading at 93.01 (down 17.38 or -15.74%) compared to its close, but also showing an after-hours price of $94.04 (up 1.03 or +1.11%).